CGT industry quality control remains constrained by viral testing challenges, according to a new analysis noting that raw material testing will likely stay central because inactivation and removal processes are difficult for cell and gene therapy products. The report highlights sensitivity limits that make many conventional viral control methods unsuitable. In parallel, real-time bioprocess monitoring is advancing as a control strategy. Researchers presented TissueSense, a label-free biosensing platform designed to monitor mammalian bioprocesses continuously and in situ, quantifying multiple biomarkers while tracking structural changes without disrupting cell environments. For next-gen workflows, automation remains a key theme. A self-driving lab “wizard” approach described using agentic AI to help students rapidly design and implement new experimental processes suggests how autonomy tooling could reduce engineering bottlenecks in research and development settings.